BioMarin Pharmaceutical
In Howard Marks's portfolio · Oaktree Capital Management
Ticker BMRN.CV
Still in the portfolio as of Q2 2026. Every quarter it shows up in a Oaktree Capital Management 13F, newest first.
| Quarter | Activity | Shares | Weight |
|---|---|---|---|
| Q2 2026 | Add 14% | 64,025,000 | 0.9% |
| Q1 2026 | Add 33% | 55,985,000 | 0.8% |
| Q4 2025 | Add 114% | 42,118,000 | 0.6% |
| Q3 2018 | Reduce 28% | 32,585,000 | 0.5% |
| Q2 2018 | Add 813% | 45,150,000 | 0.7% |
| Q4 2017 | Add 6% | 34,701,000 | 0.6% |
| Q3 2017 | Reduce 14% | 32,754,000 | 0.6% |
| Q2 2017 | Add 18% | 37,883,000 | 0.7% |
| Q1 2017 | Reduce 11% | 32,163,000 | 0.5% |
| Q4 2016 | Reduce 5% | 36,023,000 | 0.6% |
| Q3 2016 | Reduce 15% | 38,073,000 | 0.6% |
| Q2 2016 | Add 10% | 44,823,000 | 0.9% |
| Q1 2016 | Buy | 40,810,000 | 0.9% |
| Q1 2015 | Reduce 48% | 56,271,000 | 0.9% |
| Q4 2014 | Add 6% | 107,846,000 | 1.4% |
| Q3 2014 | Add 8% | 101,310,000 | 1.8% |
| Q2 2014 | Add 8% | 94,050,000 | 1.7% |
| Q1 2014 | Add 56% | 87,295,000 | 1.8% |
| Q4 2013 | Buy | 56,000,000 | 1.1% |
Price is the position's value divided by its shares, at the end of each quarter. Share counts are as filed; when a stock split happened, the change is measured on split-adjusted shares.